CNBC
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
EconomyDaily Composite
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement
